Device for detecting statin-associated myopathy through single nucleotide polymorphism rs976754 and application

Abstract

The invention provides a statin-associated myopathy detecting device. The device performs Massarray SNP genotyping detection in accordance with a single nucleotide polymorphism site rs976754 of a sample to be detected. The device comprises the following composition mechanisms of a primer synthesizing mechanism, a sample detection quantifying mechanism, a PCR reaction mechanism, a single-base extension reaction mechanism and a computer detection and analysis mechanism. The genotype at the site has important directive significance in recognizing myopathy high-risk crowds and adjusting medicationat the early stage, and has important significance in screening myopathy risk genes at the early stage, forecasting the myopathy generation risk, providing individualized medication guidance, reducing the generation of adverse drug reactions, performing prognosis and outcome of primary diseases, and improving the life quality of patients needing to take statin type blood lipid reducing medicines.

Description

technical field [0001] The invention belongs to the field of molecular biology, and in particular relates to a single nucleotide polymorphism rs976754 detection device and application for statin-related myopathy. Background technique [0002] Intracranial atherosclerosis is an independent risk factor for ischemic cerebrovascular disease, and hyperlipidemia can promote the formation of atherosclerotic plaque. Atorvastatin, as the first-line drug for lipid-lowering therapy, can competitively inhibit the rate-limiting enzyme 3-hydroxy-methylglutaryl CoA (HMG-CoA) reductase in cholesterol synthesis. Cholesterol synthesis is reduced, and at the same time, it promotes the increase of concentration-dependent LDL receptor activity, accelerates the catabolism of LDL, thereby significantly reducing blood lipid levels and stabilizing plaques, which is very beneficial to the prevention of ischemic cerebrovascular diseases. [0003] Usually the use of atorvastatin is effective and safe,...

AI Technical Summary

Problems solved by technology

Therefore, although the relationship between the SLCO1B1c.521T>C site mutation and the occurrence of myopathy has been proven, due to its limited effect, the evidence for clinical benefit of routine detection of this gene in patients is not sufficient, and most of the previous studies were Caucasian population, the gene frequency and linkage status of different ethnic groups are very different, so it is necessary to screen other SNP sites of SLCO1B1 to find the genetic cause of myopathy, predict the risk of myopathy, and reduce the occurrence of myopathy Rate

Images